Baxter Travenol is selling a unit for $425 million.

Du Pont Co. has agreed to buy American Critical Care from Baxter Travenol Laboratories, the companies announced. Du Pont said it will pay the $425 million mostly in cash, plus additional amounts based on future sales of certain patented drugs under development. American Critical Care primarily develops and manufactures hospital critical care and cardiovascular drugs. Baxter Travenol said it also has received offers to buy its Flint Laboratories unit, which makes and markets drugs to physicians.